Orgenesis Inc. (ORGS), a developer and service provider of advanced cell therapies, announced the FDA has granted Orphan Drug designation for its Autologous Insulin Producing (AIP) cells as a cell replacement therapy for the treatment of severe hypoglycemia-prone...